Skip to main content
OpenTrials
Completed

NCT Number: NCT07404540

Effect of β-alanine Supplementation and Training on Ergogenic Measures and Plasma Metabolites in Untrained Young Adults

This study enrolled untrained young adults to evaluate the effects of β-alanine supplementation combined with a structured exercise training program. Participants were randomly assigned to receive either β-alanine or a placebo while completing a six-week training regimen. Before and after the intervention, physical performance tests and blood samples were collected to assess changes in performance measures and biochemical markers in the blood. The purpose of the study was to determine how β-alanine supplementation influences exercise performance and related physiological outcomes in individuals who had not previously engaged in regular training.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Pécs

Pécs, Hungary

About this study

This randomized, double-blind, placebo-controlled study was conducted to evaluate the effects of β-alanine supplementation combined with a structured exercise training program in untrained young adults. Participants were randomly assigned to receive either β-alanine supplementation or a matching placebo while completing a six-week supervised training intervention. Both participants and investigators responsible for training supervision and outcome assessments were blinded to group allocation.

The primary outcome measures focused on changes in physical performance capacity. Maximal muscle strength was assessed using standardized dynamometric measurements, and aerobic capacity was evaluated using a validated shuttle run test performed before and after the intervention.

Secondary outcome measures included changes in anthropometric parameters, pulmonary function, and exercise-related metabolic responses. Blood lactate concentrations were measured during standardized exercise testing to characterize metabolic responses to training and supplementation. In addition, fasting venous blood samples were collected before and after the intervention to determine plasma concentrations of β-alanine, histidine, and carnosine as biochemical outcome measures related to supplementation and training adaptation.

All outcome measures were collected at baseline and following completion of the six-week intervention period. Adverse events were monitored throughout the study duration through participant self-report and investigator observation. All study procedures were performed in accordance with ethical approval and institutional guidelines.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy young adults aged 18-30 years.
  • Untrained individuals without participation in structured resistance or endurance training during the previous 6 months.
  • Not physically inactive, but not engaged in regular structured exercise training.
  • Ability to participate in a six-week supervised multicomponent exercise training program.
  • Willingness to comply with study procedures, training sessions, and supplementation protocol.
  • Provision of written informed consent.

Exclusion criteria

  • Known cardiovascular, metabolic, neuromuscular, or musculoskeletal disease.
  • Acute injury at the time of enrollment.
  • Regular use of medications or dietary supplements affecting muscle metabolism or exercise performance.
  • Participation in structured resistance or endurance training during the previous 6 months.
  • Failure to comply with the study protocol or training requirements.

Treatment and study plan

β-Alanine

Dietary Supplement

β-alanine was administered orally at a dose of 50 mg/kg/day, divided into multiple daily doses and consumed with meals, throughout the six-week training intervention.

Placebo

Dietary Supplement

Participants received visually identical placebo capsules following the same dosing schedule as the β-alanine group during the six-week training intervention.

Primary outcomes

  1. Change in maximal muscle strength

    Time frame: Baseline and 6 weeks

    Maximal muscle strength was assessed by dynamometric measurements of maximal voluntary isometric contraction.

  2. Change in aerobic capacity

    Time frame: Baseline and 6 weeks

    Aerobic capacity was estimated by VO₂max derived from the 20-m multistage fitness test (shuttle run).

Secondary outcomes

  1. Body mass index (BMI)

    Time frame: Baseline and 6 weeks

    Body mass index calculated from measured height and body mass..

  2. Body fat percentage

    Time frame: Baseline and 6 weeks

    Body fat percentage estimated from standardized skinfold thickness measurements.

  3. Forced vital capacity (FVC)

    Time frame: Baseline and 6 weeks

    Forced vital capacity measured by spirometry using a portable spirometer to assess respiratory function.

  4. Acute blood lactate response to dynamometric exercise

    Time frame: Baseline and 6 weeks

    Acute blood lactate responses were measured during standardized dynamometric exercise testing.

  5. Plasma β-alanine concentration

    Time frame: Baseline and 6 weeks

    Plasma β-alanine concentration measured from fasting venous blood samples.

  6. Plasma histidine concentration

    Time frame: Baseline and 6 weeks

    Plasma histidine concentration measured from fasting venous blood samples.

  7. Plasma carnosine concentration

    Time frame: Baseline and 6 weeks

    Plasma carnosine concentration measured from fasting venous blood samples.

Other outcomes

  1. Adverse events

    Time frame: Up to 6 weeks

    Adverse events monitored through participant self-report and investigator observation.

Sponsors and collaborators

Lead sponsor

University of Pecs

Other

Registry information

Official study title

Effect of β-alanine Supplementation and Training on Ergogenic Parameters and Plasma Metabolites in Untrained Young Adults: a Randomized, Placebo-controlled, Double-blind Trial

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Feb 11, 2026
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.